Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 182 for “"ER positive"”.
-
Mechanistic Insights into Androgen and Progesterone Receptor Mediated Tumour Suppression in ER Positive Breast Cancer
Estrogen receptor-positive (ER+) breast cancer, the most prevalent subtype (~80%), is driven by aberrant estrogen receptor (ER) signalling. Although ER-targeting endocrine therapies remain the cornerstone of treatment, therapeutic resistance is common. Steroid hormone receptors (SHRs) such as the …
-
Identifying differences in the tumour microenvironment between ER-positive and ER-negative invasive ductal breast cancer
… The tumour microenvironment is composed of different cell types, including macrophages, fibroblasts, various inflammatory cells, fat cells and endothelial cells, collectively known as stroma. Most recent studies believe that the tumour microenvironment in many solid tumours including breast …
-
Development of CDK4/6 Inhibitor Resistant ER-positive HER2-negative Breast Cancer Cell Lines to Elucidate Novel Mechanisms of Resistance
… (CDK4/6i) in combination with hormone therapy is now the standard of care for patients with advanced or metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer. However, many patients experience disease progression due to intrinsic or acquired resistance. Predictive biomarkers to …
-
BET INHIBITION AS A STRATEGY FOR ENHANCING THE RESPONSE TO ESTROGEN ANTAGONISM/CDK4-6 INHIBITION IN ER POSITIVE BREAST CANCER
Breast cancer is the most commonly occurring malignancy in females, accounting for the second most common cause of cancer-related deaths. ER+ breast cancer constitutes approximately 70% of all breast cancer cases. The standard care of therapy comprises endocrine antagonists together with adjuvant …
-
Targeting within ER positive early breast cancer: patient selection for current therapies and novel therapeutic approaches in a heterogeneous group
Over 1 million women a year are diagnosed with Breast Cancer. The majority, approximately 70% express the oestrogen receptor (ER). ER positive breast cancer has historically been perceived as a ‘good cancer’, although many woman with ER+ breast cancer still succumb to their disease and globally …
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
COMBINED INHIBITION OF DDR1 AND CDK4/6 INDUCES SYNERGISTIC EFFECTS IN ER-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH PIK3CA/AKT1 MUTATIONS Maryam Shariati, M.S. Advisory Professor: Funda Meric-Bernstam, M.D. Molecular alterations in the phosphatidylinositol 3‑kinase (PI3K)/ serine/threonine protein …
-
Anti-carcinogenic effects of Morinda citrifolia (noni): identifying signal transduction pathways using ER positive and ER negative human breast cancer cell lines
It is predicted that one in every eight women in the United States will be diagnosed with breast cancer in her lifetime, making breast cancer the second most prevalent cancer in the nation. Native Hawaiians have the highest incidence as well as mortality rates compared to other ethnic groups in …
-
A role for MP1 scaffold protein in breast cancer cells
Breast cancer cells are characterized by their uncontrolled proliferation, high motility and ability to escape cell death. These pathophysiological processes are driven by aberrant expression and activity of various intracellular pathways, including ER, PI3K/AKT/mTOR, MAPK and integrins. Activated …
-
Comprehensive gene assessment of estrogen receptor positive breast cancers reveals that HER2 positive status plays an important role in resistance to neoadjuvant letrozole
Background The ER positive/ HER2 positive molecular subtype accounts for up to 10% of all breast cancers, these cancers have a worse prognosis than ER positive/ HER2 negative breast cancers. There is considerable evidence that ER positive/ HER2+ positive cancers exhibit resistance to endocrine …
-
Expression of Human Estrogen Receptor and Studies of Estrogen-Mediated Transcription and Apoptosis
… each induce apoptosis in stably transfected hER positive HeLa-ER5 cells. Using transient transfections and a reporter system to measure p38 activity, we show that E2 induces the p38 activity 12--36 fold in several ER positive cell lines, while OHT induces p38 activity 2--5 fold. A selective …
-
Androgen Receptor: A Complex Therapeutic Target in Breast Cancer
Breast cancer is classified based on the expression of three markers estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor (HER2). Breast cancers that express these targets are classified as hormone receptor (HR) positive breast cancer and the tumors that lack …
-
The role of IKKalpha, IKKbeta and NF-kappaB in the progression of breast cancer
Breast cancer is the most common female cancer in the UK and, despite earlier detection and improved treatments, remains the second most common cause of cancer death in women. Although therapies exist for breast cancer, including endocrine therapy for oestrogen receptor (ER) positive tumours, …
-
Cell cycle deregulation in breast cancer subgroups and effects on proliferation, migration and tamoxifen resistance
Breast cancer is a heterogenous disease which can be divided in subgroups of distinct biology with disparate prognosis and response to treatment. The overall aim of this thesis was to delineate subgroup specific behaviour in breast cancer cells with focus on proliferation, migration and stem-like …
-
The estrogen receptor functions as an inhibitor of NF-kappaB
… resistance has been correlated with changes in ERalpha expression/mutation and a rise in NF-kappaB activity. We believe that NF-kappaB is activated in both ER-positive and ER-negative breast cancer cells and that it is attenuated by liganded ERalpha in ER-positive cells by regulating the …
-
Targeting Downstream Effectors of IGF/Insulin Signaling System in Human Breast Cancer
… multiple intracellular pathways. In breast cancer cells, the type I insulin-like growth factor receptor (IGF-IR) has been implicated of tumorigenicity, proliferation, and metastasis. However, clinical trials with anti-IGF-IR monoclonal antibodies have generally been disappointing, partially due …
-
The impact of socio-economic factors on outcome from breast cancer
… that a deprivation gap exists in breast cancer. The aim of this thesis is to identify if there remains a survival gap between affluent and deprived women and to what extent treatment and pathology are responsible. All women treated for primary operable invasive breast cancer in Glasgow …
-
Targeting ribonucleotide reductase for breast cancer treatment
Breast cancer is the second most common type of cancer in the world. Hormone receptor (HR) positive breast cancer (BC) is a prevalent disease accounting for approximately 2 million new cases globally. Almost 70-80% of breast cancer patients are women with a positive score for the estrogen receptor …
-
Estrogen Receptor Beta and p53 Signaling Crosstalk in Triple Negative Breast Cancer
… prognostic tool in the management of breast cancer. For ER-positive breast cancers, this means better prognosis, more available treatment options, lower recurrence rates, and better overall survival. Meanwhile, ER-negative breast cancers have more aggressive disease phenotypes and fewer treatment …
Page 1 of 10